Tibotec’s next-generation NNRTI, rilpivirine (previously known as TMC278) continues to suppress viral load and increase CD4 counts in similar numbers of treatment-naïve patients to efavirenz (Sustiva) over 96 weeks according to Phase IIb study data presented to the recent XVII International AIDS Conference in Mexico City. When compared to efavirenz, however, rilpivirine appears to produce a lower incidence of rash, central nervous system disorders, and lipid abnormalities
http://www.aidsmap.org/en/news/4458BE13-A6E2-49CA-B795-F5FA101509F2.asp